Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trimebutine maleate + Clostridium butyricum
- Development stage
- Unknown
- Lead developer
- Hainan Poly
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
This is a combination drug consisting of trimebutine maleate, a gastrointestinal motility modulator, and Clostridium butyricum, a probiotic bacterium. Trimebutine maleate acts as a non-competitive spasmolytic agent with mild opioid receptor affinity and significant anti-serotonin activity. It regulates gastrointestinal motility by exerting both stimulatory and inhibitory effects on intestinal smooth muscle, making it effective for treating symptoms of irritable bowel syndrome (IBS), including abdominal pain, bloating, diarrhea, and constipation[2][4][5]. Clostridium butyricum is an anaerobic gram-positive bacillus used as a probiotic to restore gut flora balance. It produces butyrate—a short-chain fatty acid essential for colon health—supports the integrity of the gut barrier, inhibits pathogenic bacteria growth through bacteriocin production, enhances nutrient absorption, and modulates immune responses[6][8]. The combination targets both functional dysregulation (via trimebutine) and microbiota imbalance (via C. butyricum), providing comprehensive management for gastrointestinal disorders such as IBS-D (diarrhea-predominant IBS)[1].
- Other names
- 马来酸曲美布汀 + 酪酸梭活菌
02
Targets
FFAR3 (Free fatty acid receptor 3)MOR (Mu opioid receptor)5-HT (Serotonin receptors)
Beyond the preview
Go deeper on trimebutine maleate + Clostridium butyricum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trimebutine maleate + Clostridium butyricum.